{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chronic+Liver+Disease&page=2",
    "query": {
      "condition": "Chronic Liver Disease",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chronic+Liver+Disease&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T13:25:11.161Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03902366",
      "title": "HCV and Co-morbid Alcohol Use Disorders: A Translational Investigation of Antiviral Therapy Outcomes on CNS Function",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hepatitis C",
        "Alcohol Use Disorder"
      ],
      "interventions": [
        {
          "name": "Neuropsychological assessment",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Neuroimaging",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST",
        "BEHAVIORAL"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 63,
      "start_date": "2019-05-16",
      "completion_date": "2023-12-29",
      "has_results": true,
      "last_update_posted_date": "2025-03-27",
      "last_synced_at": "2026-06-10T13:25:11.161Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03902366"
    },
    {
      "nct_id": "NCT01439373",
      "title": "Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C, Chronic"
      ],
      "interventions": [
        {
          "name": "GSK2336805",
          "type": "DRUG"
        },
        {
          "name": "Pegylated interferon alfa-2a",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        },
        {
          "name": "GSK2336805 Matching Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 16,
      "start_date": "2011-07-07",
      "completion_date": "2011-12-05",
      "has_results": true,
      "last_update_posted_date": "2017-12-11",
      "last_synced_at": "2026-06-10T13:25:11.161Z",
      "location_count": 9,
      "location_summary": "Anaheim, California • Chula Vista, California • Coronado, California + 6 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Coronado",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Oceanside",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01439373"
    },
    {
      "nct_id": "NCT00295061",
      "title": "Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alpha 1-Antitrypsin Deficiency"
      ],
      "interventions": [
        {
          "name": "Alpha-1 MP",
          "type": "DRUG"
        },
        {
          "name": "alpha-1 proteinase inhibitor (human)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Grifols Therapeutics LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2006-05",
      "completion_date": "2007-02",
      "has_results": true,
      "last_update_posted_date": "2014-09-09",
      "last_synced_at": "2026-06-10T13:25:11.161Z",
      "location_count": 8,
      "location_summary": "Denver, Colorado • Gainesville, Florida • Miami, Florida + 5 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00295061"
    },
    {
      "nct_id": "NCT01962441",
      "title": "SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "SOF",
          "type": "DRUG"
        },
        {
          "name": "RBV",
          "type": "DRUG"
        },
        {
          "name": "Peg-IFN",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 601,
      "start_date": "2013-09-24",
      "completion_date": "2016-07-07",
      "has_results": true,
      "last_update_posted_date": "2017-06-20",
      "last_synced_at": "2026-06-10T13:25:11.161Z",
      "location_count": 23,
      "location_summary": "Riverside, California • San Diego, California • San Francisco, California + 19 more",
      "locations": [
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Englewood",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01962441"
    },
    {
      "nct_id": "NCT02123212",
      "title": "Birth-Cohort Evaluation to Advance Screening and Testing for Hepatitis C",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hepatitis C",
        "Chronic Hepatitis C"
      ],
      "interventions": [
        {
          "name": "Mailer",
          "type": "OTHER"
        },
        {
          "name": "In-person recruitment",
          "type": "OTHER"
        },
        {
          "name": "EHR Alert",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "National Opinion Research Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "47 Years",
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "47 Years to 69 Years"
      },
      "enrollment_count": 29607,
      "start_date": "2013-02",
      "completion_date": "2014-03",
      "has_results": false,
      "last_update_posted_date": "2015-03-26",
      "last_synced_at": "2026-06-10T13:25:11.161Z",
      "location_count": 3,
      "location_summary": "Birmingham, Alabama • Detroit, Michigan • New York, New York",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02123212"
    },
    {
      "nct_id": "NCT04535544",
      "title": "A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis D, Chronic"
      ],
      "interventions": [
        {
          "name": "JNJ-73763989",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Entecavir (ETV) monohydrate",
          "type": "DRUG"
        },
        {
          "name": "Tenofovir disoproxil",
          "type": "DRUG"
        },
        {
          "name": "Tenofovir alafenamide (TAF)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 52,
      "start_date": "2020-09-17",
      "completion_date": "2025-03-05",
      "has_results": true,
      "last_update_posted_date": "2025-04-25",
      "last_synced_at": "2026-06-10T13:25:11.161Z",
      "location_count": 2,
      "location_summary": "Redwood City, California • Boston, Massachusetts",
      "locations": [
        {
          "city": "Redwood City",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04535544"
    },
    {
      "nct_id": "NCT01687257",
      "title": "Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C",
        "Cirrhosis",
        "Portal Hypertension",
        "With or Without Liver Decompensation"
      ],
      "interventions": [
        {
          "name": "SOF",
          "type": "DRUG"
        },
        {
          "name": "RBV",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2012-07",
      "completion_date": "2015-10",
      "has_results": true,
      "last_update_posted_date": "2016-09-16",
      "last_synced_at": "2026-06-10T13:25:11.161Z",
      "location_count": 4,
      "location_summary": "Aurora, Colorado • Boston, Massachusetts • Rochester, Minnesota + 1 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01687257"
    },
    {
      "nct_id": "NCT00040144",
      "title": "Safety and Antiviral Study of ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Hepatitis B"
      ],
      "interventions": [
        {
          "name": "ACH126, 433",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 85,
      "start_date": "2002-07",
      "completion_date": "2003-05",
      "has_results": false,
      "last_update_posted_date": "2021-02-18",
      "last_synced_at": "2026-06-10T13:25:11.161Z",
      "location_count": 13,
      "location_summary": "Los Angeles, California • Orange, California • Pasadena, California + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00040144"
    },
    {
      "nct_id": "NCT06537414",
      "title": "A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Hepatitis B Virus Infection",
        "Hepatitis B"
      ],
      "interventions": [
        {
          "name": "Daplusiran/Tomligisiran Dose Level 1",
          "type": "DRUG"
        },
        {
          "name": "Daplusiran/Tomligisiran Dose Level 2",
          "type": "DRUG"
        },
        {
          "name": "Bepirovirsen",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 283,
      "start_date": "2024-11-11",
      "completion_date": "2027-05-31",
      "has_results": false,
      "last_update_posted_date": "2025-07-28",
      "last_synced_at": "2026-06-10T13:25:11.161Z",
      "location_count": 5,
      "location_summary": "San Francisco, California • San Jose, California • Minneapolis, Minnesota + 2 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Jose",
          "state": "California"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06537414"
    },
    {
      "nct_id": "NCT02292706",
      "title": "A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hepatitis C Virus Infection"
      ],
      "interventions": [
        {
          "name": "Sofosbuvir",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        },
        {
          "name": "LDV/SOF",
          "type": "DRUG"
        },
        {
          "name": "SOF/VEL",
          "type": "DRUG"
        },
        {
          "name": "SOF/VEL/VOX",
          "type": "DRUG"
        },
        {
          "name": "Other SOF-Based Regimen",
          "type": "DRUG"
        },
        {
          "name": "Ineligible parent treatment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1609,
      "start_date": "2014-12-29",
      "completion_date": "2021-12-31",
      "has_results": true,
      "last_update_posted_date": "2023-10-04",
      "last_synced_at": "2026-06-10T13:25:11.161Z",
      "location_count": 77,
      "location_summary": "Birmingham, Alabama • La Jolla, California • Long Beach, California + 57 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02292706"
    }
  ]
}